

Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of Multiple Sclerosis

Xiaofang Wang, Erin A. Kimbrel, Kumiko Ijichi, Debayon Paul, Adam S. Lazorchak, Jianlin Chu, Nicholas A. Kouris, Gregory J. Yavarian, Shi-Jiang Lu, Joel S. Pachter, Stephen J. Crocker, Robert Lanza,* and Ren-He Xu*

*Correspondence: rlanza@advancedcell.com (R.L.), renhe.xu@imstem.com (R.-H.X.)
<https://doi.org/10.1016/j.stemcr.2021.01.004>

(Stem Cell Reports 3, 115–130; July 8, 2014)

In the originally published version of our paper, the wrong data was used to generate Figure 4A: the hES-MSC line used to generate the figure was not the hES-MSC(MA09) line stated in the figure legend; instead, an hES-MSC line generated via another method, which was not described in the paper, was used. This mistake was uncovered during a recent internal data review.

A correct version of Figure 4 now appears below. The altered figure does not affect the results and conclusion of the paper.

We apologize for the oversight and for any confusion it has caused.




Figure 4. Effects of hES-MSCs and BM-MSCs on T Cell Functions In Vitro